The rise of AI is reshaping our world rapidly. As this technology continues to advance, it’s poised to significantly alter numerous industries by boosting workforce productivity, improving operational efficiencies, and bringing about remarkable advancements.
Ever since the game-changing launch of ChatGPT in January 2023, there’s been a surge in investment in companies at the forefront of AI, leading to a notable increase in valuations across this diverse landscape. However, amidst all this excitement, some promising AI firms are, surprisingly, undervalued when considering their long-term potential.
Two companies in particular are noteworthy for their strategic roles within the AI ecosystem. They are positioned to benefit greatly from the rising use of AI in both corporate and consumer sectors. Still, their current market assessments don’t quite capture their competitive advantages or growth prospects. For investors keen to explore the AI revolution without shelling out a premium, these two stocks are definitely worth a look.
Nuclear Power Reinvented
Oklo (OKLO) illustrates the powerful fusion of AI and advanced nuclear technology. The firm employs cutting-edge AI algorithms to enhance the design and operational efficiency of compact, rapid reactors. This microreactor is explicitly created to deliver clean, reliable energy to data centers that are ever-hungry for power.
This approach directly tackles one of the most significant yet often overlooked issues tied to the AI boom—its substantial energy demands. According to the Center for Global Energy Policy, US data centers might need more than 14 gigawatts of new capacity by 2030, which is roughly equivalent to the energy consumption of around 10.5 million households. This trend is even more pronounced in countries like Ireland, where data centers could consume up to 32% of total energy production.
Oklo’s strengths lie in both speed and precision. AI-driven design processes can shorten development timelines and cut costs in sectors facing delays and regulatory hurdles. Additionally, these microreactors can be deployed on-site, eliminating energy transmission losses while providing localized, carbon-free power to support AI infrastructures.
Even with a remarkable annual growth rate of 32% as of May 9, 2025, Oklo’s market valuation remains relatively modest at $3.9 billion. This seems low, especially given the impending energy constraints that could hinder AI’s growth. As computational demands for advanced AI systems keep rising, Oklo’s solutions go beyond just alternative energy; they are crucial for propelling the next chapter of AI development. For investors interested in unique yet vital elements of the AI revolution, Oklo presents an intriguing option at current price points.
Innovative Drug Discovery
Recursion Pharmaceuticals (RXRX) is transforming drug development on an industrial scale through the use of AI. Central to its strategy is Recursion OS, a distinctive platform that integrates one of the world’s most powerful supercomputers with extensive biological and chemical datasets. This system leverages machine learning to conduct millions of automated experiments weekly, mapping trillions of relationships in human biology and chemistry.
In May 2025, Recursion narrowed its focus on groundbreaking clinical programs in oncology and rare diseases, strategically streamlining its pipeline following data-driven assessments. Its main candidates—REC-4881 for familial adenomatous polyposis and REC-7735 in breast cancer—are showing encouraging early results.
The company is also enhancing its partnership network, having recently secured a $7 million milestone payment from Sanofi while continuing collaborations with Roche and Merck Kgaa.
The AI-first approach of Recursion enables quicker and more precise therapeutic discoveries, significantly trimming development costs—a vital advantage in this capital-heavy, high-risk sector. With $509 million in cash and funding secured through mid-2027, Recursion is well-equipped to navigate market fluctuations while advancing its new platform and valuable pipeline.
Despite these strong indicators, its stock has experienced a 35% drop, bringing its market cap down to $1.76 billion. As AI technology continues to disrupt traditional drug discovery methods, Recursion stands out as an underrated leader at the intersection of machine learning and medicine, poised to unlock the next generation of precise therapies.
